| [1] |
Maggs JR, Suddle AR, Aluvihare V, et al. Systematic review: the role of liver transplantation in the management of hepatocellular carcinoma[J]. Aliment Pharmacol Ther, 2012, 35(10):1113-1134. doi: 10.1111/apt.2012.35.issue-10
|
| [2] |
Chan SC, Fan ST. Selection of patients of hepatocellular carcinoma beyond the Milan criteria for liver transplantation[J].Hepatobiliary Surg Nutr, 2013, 2(2):84-88. http://cn.bing.com/academic/profile?id=1954044696&encoded=0&v=paper_preview&mkt=zh-cn
|
| [3] |
Patel SS, Arrington AK, McKenzie S, et al. Milan criteria and UCSF criteria: a preliminary comparative study of liver transplantation Outcomes in the United States[J]. Int J Hepatol, 2012:253517. http://cn.bing.com/academic/profile?id=2045754216&encoded=0&v=paper_preview&mkt=zh-cn
|
| [4] |
Ataide EC, Boin IF, Almeida JR, et al. Prognostic factors for hepatocellular carcinoma recurrence: experience with 83 liver transplantation patients[J].Transplant Proc, 2011, 43(4):1362-1364. doi: 10.1016/j.transproceed.2011.02.032
|
| [5] |
Taniguchi M. Liver transplantation in the MELD era:analysis of the OPTN/UNOS registry[J]. Clin Transpl, 2012:41-65. http://cn.bing.com/academic/profile?id=81283163&encoded=0&v=paper_preview&mkt=zh-cn
|
| [6] |
Toso C, Majno P, Berney T, et al. Validation of a dropout assessment model of candidates with/without hepatocellular carcinoma on a common liver transplant waiting list[J]. Transpl Int, 2014, DOI: 10.1111/tri.12323[Epub ahead of print].
|
| [7] |
Ashoori N, Bamberg F, Paprottka P, et al. Multimodality treatment for early-stage hepatocellular carcinoma: a bridging therapy for liver transplantation[J].Digestion, 2012, 86(4):338-348. doi: 10.1159/000342813
|
| [8] |
Cescon M, Cucchetti A, Ravaioli M, et al. Hepatocellular carcinoma locoregional therapies for patients in the waiting list. impact on transplantability and recurrence rate[J]. J Hepatol, 2013, 58(3):609-618. doi: 10.1016/j.jhep.2012.09.021
|
| [9] |
Tremosini S, Forner A, Boix L, et al. Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma[J]. Gut, 2012, 61(10):1481-1487. doi: 10.1136/gutjnl-2011-301862
|
| [10] |
Wang NY, Wang C, Li W, et al. Prognostic value of serum AFP, AFP-L3, and GP73 in monitoring short-term treatment response and recurrence of hepatocellular carcinoma after radiofrequency ablation[J]. Asian Pac J Cancer Prev, 2014, 15(4):1539-1544. doi: 10.7314/APJCP.2014.15.4.1539
|
| [11] |
Villanueva A, Hoshida Y, Toffanin S, et al. New strategies in hepatocellular carcinoma: genomic prognostic markers[J]. Clin Cancer Res, 2010, 16(19):4688-4694. doi: 10.1158/1078-0432.CCR-09-1811
|
| [12] |
Vivarelli M, Dazzi A, Cucchetti A, et al. Sirolimus in liver transplant recipients: a large single-center experience[J]. Transplant Proc, 2010, 42(7):2579-2584. doi: 10.1016/j.transproceed.2010.04.045
|
| [13] |
Teng CL, Hwang WL, Chen YJ, et al. Sorafenib for hepatocellular carcinoma patients beyond Milan criteria after orthotopic liver transplantation: a case control study[J]. World J Surg Oncol, 2012, 10:41. doi: 10.1186/1477-7819-10-41
|
| [14] |
Vakili K, Pomposelli JJ, Cheah YL, et al. Living donor liver transplantation for hepatocellular carcinoma: increased recurrence but improved survival[J]. Liver Transpl, 2009, 15(12):1861-1866. doi: 10.1002/lt.v15:12
|
| [15] |
Chao SD, Roberts JP, Farr M, et al. Short waitlist time does not adversely impact outcome following liver transplantation for hepatocellular carcinoma[J]. Am J Transplant, 2007, 7(6):1594-1600. doi: 10.1111/ajt.2007.7.issue-6
|
Figures(2) / Tables(1)
WeChat Subscription Account
Wechat Service Account
Supported by:
Beijing Renhe Information Technology Co. Ltd
DownLoad:
